deep vein thrombosis (DVT)Standard anticoagulant treatment alone for acute lYongmingDepartmentLuDepartmentLinyiDepartmentChenDepartmentJinhuiDepartmentChenDepartmentTaoDepartmentTangDepartmentClinical and applied thrombosis/hemostasisLu Y, Chen L, Chen J, Tang T. Catheter-directed thrombolysis versus standard ...
〽For VTE associated with cancer, LMWH is recommended over VKA or any DOACs. 〽Anticoagulants should stop after 3 months in patients with acute, proximal DVT or PE provoked by surgery only or have high bleeding risk. Then u...
Conclusion: Prescription of anticoagulation is quite variable in patients admitted to ICU for Covid-19 associated ARDS. Anticoagulation dosing strategy has no significant effect on 28-day survival, LOSICU, the occurrence of DVT, PE, or bleeding....
Deep vein thrombosis (DVT) is a serious condition which can be complicated by the development of pulmonary embolism, which has a high mortality and morbidi... JR Harding,AM Wright - International Conference of the IEEE Engineering in Medicine & Biology Society 被引量: 7发表: 1996年 加载更多来...
Heparin or low molecule weight heparin ( LMWH )anticoagulationwas effective treatment in postoperative DVT. 治疗采用肝素或低分子肝素如速避凝抗凝治疗,均取得较好效果. 互联网 If the patient continues to bleed, reversal of theanticoagulationmay be with fresh frozen plasma. ...
Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): ... Conventional anticoagulant treatment for acute deep vein thrombosis (DVT) effectively prevents thrombus extension and recurrence, but does not disso...
In patients with unprovoked first events, the DASH score had a similar predictive value for DVT and PE, both when calculated using Vidas D-dimer or ... HVA Van,CA Baglin,R Luddington,... - 《Journal of Thrombosis & Haemostasis》 被引量: 22发表: 2015年 The risk of recurrent thromboembol...
those with levels <0.1 IU/mL had an increased risk of developing DVT [208]. However, this study also found that increased body weight partially correlated with low anti-Xa activity. Nevertheless, 12-h/trough anti-Xa monitoring of LMWH for VTE thromboprophylaxis in high risk critically ill...
The novel anticoagulant rivaroxaban [BAY 59-7939], a selective Factor Xa inhibitor, is a promising investigational oral anticoagulant for both the acute treatment and long-term secondary prevention of deep vein thrombosis (DVT), according to two phase II dose-finding studies presented at the 48th...
Conclusion We have established feasibility for a definitive trial on the value of therapeutic anticoagulation for IDDVT. Our pilot study currently provides the largest prospective randomised clinical dataset on this topic and demonstrates a non-significant trend towards reduction in complications with ...